Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth

Bioventus Inc.

Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).
FY2024 revenue $573.3M (+11.9%); net loss $43.8M vs ($121.2M); adj EBITDA $108.9M (+22.5%).
FY2025 guidance: net sales $560-570M, adj EBITDA $112-116M, non-GAAP EPS $0.64-$0.68.
Debt reduced by $48.3M in Q4; Advanced Rehabilitation Business divested for $24.7M proceeds.
Pain Treatments and Surgical Solutions each delivered double-digit revenue growth for fifth straight quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.